We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

By LabMedica International staff writers
Posted on 13 Apr 2015
Print article
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).
An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.

The drug, AZD05030 (Saracatinib), developed by Astra Zeneca (London, United Kingdom) is a potent Src inhibitor to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR. As investigators at Yale University (New Haven, CT, USA) were aware that the Fyn tyrosine kinase was implicated in AD pathology where it was triggered by amyloid-beta oligomers (A-beta o) and propagated by Tau; the theorized that Fyn inhibition would prevent or delay disease progression.

To this end they sought to repurpose the Src family kinase inhibitor cancer drug, AZD0530, for AD. Initially they evaluated the pharmacokinetics and distribution of AZD0530 in mice. Inhibition of A-beta o signaling to Fyn, Pyk2, and Glu receptors by AZD0530 was tested by brain slice assays. After AZD0530 or vehicle treatment of wild-type and AD transgenic mice, memory was assessed by Morris water maze and novel object recognition. For these cohorts, amyloid precursor protein (APP) metabolism, synaptic markers (SV2 and PSD-95), and targets of Fyn (Pyk2 and Tau) were studied by immunohistochemistry and by immunoblotting.

Results published in the March 21, 2015, online edition of the journal Annals of Neurology revealed that AZD0530 potently inhibited Fyn and prevented both A-beta o-induced Fyn signaling and downstream phosphorylation of the AD risk gene product Pyk2 in brain slices. After four weeks of treatment, AZD0530 dosing of APP/PS1 transgenic mice fully rescued spatial memory deficits and synaptic depletion, without altering APP or A-beta metabolism. AZD0530 treatment also reduced microglial activation in APP/PS1 mice, and rescued Tau phosphorylation and deposition abnormalities in APP/PS1/Tau transgenic mice. There was no evidence of AZD0530 chronic toxicity.

"With this treatment, cells under bombardment by beta amyloid plaques show restored synaptic connections and reduced inflammation, and the animal's memory, which was lost during the course of the disease, comes back," said senior author Dr. Stephen M. Strittmatter, professor of neurology at Yale University.

Related Links:

Yale University


Gold Member
Turnkey Packaging Solution
HLX
Automated Blood Typing System
IH-500 NEXT
New
Silver Member
Oncology Molecular Diagnostic Test
BCR-ABL Dx ELITe MGB Kit
New
Malaria Rapid Test
OnSite Malaria Pf/Pan Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.